IGC Pharma Inc

NYSE American:IGCUnited States

IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Contact Information

Headquarters

2405 York Road, Suite 201LUTHERVILLE-TIMONIUM, MD, United States 21093-2264

Phone

301-983-0998

Fax

240-465-0273

Executives

Independent Chairman of the Board

Richard Prins

President, Chief Executive Officer, Director

Ram Mukunda

Vice-President, Principal Financial Officer, Chief Compliance Officer, Director

Claudia Grimaldi

Independent Director

Terry Lierman

Independent Director

James Moran